Evidence mapPaperPMID 41209563Full record

ReviewInternational journal of medical sciences2025

Advances in Tumor Antigen Vaccines: A New Frontier in Cancer Immunotherapy.

Wanqi Feng, Yifan Zhao, Dongran Yu, Wenyu Jia, Hui Cao, Yuling Zhang, Jie Cao, Zequn Li

Abstract readReview
In one paragraph

Review in International journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wanqi FengDepartment of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266000, China.
Yifan ZhaoDepartment of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, 266071, China.
Dongran YuDepartment of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266000, China.
Wenyu JiaDepartment of Endocrinology, Qingdao Municipal Hospital, Qingdao, 266071, China.
Hui CaoDepartment of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266000, China.
Yuling ZhangDepartment of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266000, China.
Jie CaoDepartment of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, 266071, China.
Zequn LiDepartment of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the increasing prominence of cancer immunotherapy, therapeutic tumor vaccines have emerged as a promising strategy to enhance antitumor immunity by increasing tumor immunogenicity and activating the patient's immune system to inhibit tumor growth. However, their clinical efficacy is often limited due to insufficient immune cell infiltration, low antigen immunogenicity, and tumor immune escape mechanisms. To address these challenges, various innovative approaches have been explored, including the optimization of tumor antigen selection, the development of advanced vaccine platforms, and the combination of vaccines with other treatment strategies such as radiotherapy, chemotherapy, immune checkpoint inhibitors (ICIs), cytokine therapy, and adoptive T-cell transfer. This review provides a comprehensive summary of the mechanisms underlying tumor antigen vaccines, discusses recent advancements in vaccine design and combinatorial strategies, and assesses their potential to enhance therapeutic outcomes. We also highlight the ongoing challenges and future directions, underscoring the importance of interdisciplinary efforts to realize the full potential of tumor vaccines as a foundation of personalized cancer immunotherapy.

Indexed as

Antigens, NeoplasmCancer VaccinesImmunotherapyNeoplasmsAnimalsCombined Modality TherapyHumansImmune Checkpoint InhibitorsPrecision MedicineAntigens, NeoplasmCancer VaccinesImmune Checkpoint InhibitorsCombination therapy.Tumor antigen vaccinesTumor-associated antigensTumor-specific antigensVaccine platforms

Identifiers

PMID41209563
PMCPMC12595338

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.